BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38557171)

  • 1.
    Chen L; Shashkina E; Kurepina N; Calado Nogueira de Moura V; Daley CL; Kreiswirth BN
    Antimicrob Agents Chemother; 2024 May; 68(5):e0017424. PubMed ID: 38557171
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus.
    Rominski A; Schulthess B; Müller DM; Keller PM; Sander P
    J Antimicrob Chemother; 2017 Nov; 72(11):3070-3078. PubMed ID: 28961987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors.
    Dousa KM; Kurz SG; Taracila MA; Bonfield T; Bethel CR; Barnes MD; Selvaraju S; Abdelhamed AM; Kreiswirth BN; Boom WH; Kasperbauer SH; Daley CL; Bonomo RA
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32393499
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex
    Pandey R; Chen L; Manca C; Jenkins S; Glaser L; Vinnard C; Stone G; Lee J; Mathema B; Nuermberger EL; Bonomo RA; Kreiswirth BN
    mBio; 2019 Feb; 10(1):. PubMed ID: 30755518
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Yamatani I; Aono A; Fujiwara K; Asami T; Kamada K; Morishige Y; Igarashi Y; Chikamatsu K; Murase Y; Yamada H; Takaki A; Komiya K; Mitarai S
    Microbiol Spectr; 2024 Jul; 12(7):e0008424. PubMed ID: 38842354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action.
    Dousa KM; Nguyen DC; Kurz SG; Taracila MA; Bethel CR; Schinabeck W; Kreiswirth BN; Brown ST; Boom WH; Hotchkiss RS; Remy KE; Jacono FJ; Daley CL; Holland SM; Miller AA; Bonomo RA
    mBio; 2022 Feb; 13(1):e0352921. PubMed ID: 35073757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.
    Asempa TE; Kois AK; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2022 Sep; 77(10):2622-2631. PubMed ID: 35325165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal and intracellular activity of β-lactams against Mycobacterium abscessus.
    Lefebvre AL; Dubée V; Cortes M; Dorchêne D; Arthur M; Mainardi JL
    J Antimicrob Chemother; 2016 Jun; 71(6):1556-63. PubMed ID: 26929268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus.
    Raynaud C; Daher W; Roquet-Banères F; Johansen MD; Stec J; Onajole OK; Ordway D; Kozikowski AP; Kremer L
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.
    Asempa TE; Kois AK; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2023 Mar; 78(3):636-645. PubMed ID: 36626311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem.
    Le Run E; Atze H; Arthur M; Mainardi JL
    J Antimicrob Chemother; 2020 Feb; 75(2):379-383. PubMed ID: 31637424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual β-lactam therapy to improve treatment outcome in Mycobacterium abscessus disease.
    Pozuelo Torres M; van Ingen J
    Clin Microbiol Infect; 2024 Jun; 30(6):738-742. PubMed ID: 38527611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.
    Lopeman RC; Harrison J; Rathbone DL; Desai M; Lambert PA; Cox JAG
    Sci Rep; 2020 Jan; 10(1):928. PubMed ID: 31988293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the β-Lactamase Bla
    Lefebvre AL; Le Moigne V; Bernut A; Veckerlé C; Compain F; Herrmann JL; Kremer L; Arthur M; Mainardi JL
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096155
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against
    Dousa KM; Shin E; Kurz SG; Plummer M; Nantongo M; Bethel CR; Taracila MA; Nguyen DC; Kreiswith BN; Daley CL; Remy KE; Holland SM; Bonomo RA
    mBio; 2024 Jun; 15(6):e0060924. PubMed ID: 38742824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
    Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
    Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.